GRCE (Grace Therapeutics) Total Liabilities: $2.76 Mil (As of Mar. 2026)


GRCE Grace Therapeutics Inc GRCE
31 GF Score
Price $2.35
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics Total Liabilities?

Grace Therapeutics GRCE +1.06% 31 Total Liabilities is $2.76 Mil as of Mar. 2026. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Grace Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $2.76 Mil.

Grace Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($3.76 Mil) to Dec. 2025 ($3.60 Mil) and declined from Dec. 2025 ($3.60 Mil) to Mar. 2026 ($2.76 Mil).

Grace Therapeutics's annual Total Liabilities declined from Mar. 2024 ($11.56 Mil) to Mar. 2025 ($5.38 Mil) and declined from Mar. 2025 ($5.38 Mil) to Mar. 2026 ($2.76 Mil).

Grace Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Grace Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grace Therapeutics Total Liabilities Chart

Grace Therapeutics Annual Data
Trend Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.35 11.17 11.56 5.38 2.76

Grace Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.38 6.26 3.76 3.60 2.76
GRCE
31GF Score
Grace Therapeutics Inc GRCE
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Grace Therapeutics's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.146+(0+1.1102230246252E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.612+0+0)
=2.76

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=66.654-63.896
=2.76

Grace Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.146+(0+1.1102230246252E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.612+0+0)
=2.76

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=66.654-63.896
=2.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $2.76 Mil mean?
Grace Therapeutics (GRCE) has a Total Liabilities of $2.76 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Grace Therapeutics and its competitors.
Is Grace Therapeutics' Total Liabilities too high?
Grace Therapeutics' current Total Liabilities is $2.76 Mil. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' Total Liabilities compare to PSTV and ATNM?
Grace Therapeutics' Total Liabilities of $2.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Grace Therapeutics and its competitors. Grace Therapeutics's current Total Liabilities is $2.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current Total Liabilities of $2.76 Mil. The current Total Liabilities is $2.76 Mil. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current Total Liabilities is $2.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grace Therapeutics Business Description

Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score

Get the complete analysis for GRCE

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.35
Price